News | January 11, 2026
PAI Pharma acquires Nivagen to boost US injectable drug production
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
DengiAll will be the first indigenous single-shot dengue vaccine in India and is expected to enter the markets by 2027
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
Subscribe To Our Newsletter & Stay Updated
